Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Mechanistic insights into cancer-associated thrombosis in brain cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Cancer-associated thrombosis (CAT) is an umbrella term describing multiple forms of deregulated hemostasis and clotting related to cancer progression or therapy. Venous thromboembolism (VTE) is the most prevalent and widely studied systemic manifestation of CAT associated with considerable morbidity and risk of life-threatening pulmonary embolism (PE). While some aspects of CAT may be unspecific or iatrogenic, the biology of cancer cells contributes to this condition through the expression of the procoagulant phenotype, often attributable to upstream oncogenic mutations, the state of the epigenome, and influences of the tumor microenvironment (TME). High-grade astrocytic brain tumors (HGGs) are among the most procoagulant neoplastic disease states. Podoplanin (PDPN) and tissue factor (TF) have been implicated in HGG-associated VTE risk, while isocitrate dehydrogenase (IDH) mutations protect from thrombosis in HGG. Highly procoagulant, IDH-wild-type HGGs, such as glioblastoma (GBM), represent a cluster of disease states, each comprising cellular populations endowed with different repertoires of TF and PDPN expression. GBM cells project their influence systemically, at least in part, through the release of extracellular vesicles (EVs) carrying TF, PDPN, and other factors. The specific roles of these mechanisms in GBM-associated VTE are under investigation. Given the intense interest in developing new treatment strategies in GBM, the interplay between these interventions and the activity of the hemostatic system is of paramount importance. Indeed, a better understanding of mechanisms driving CAT in molecular and therapeutic contexts of specific brain tumor subtypes could inform more individualized approaches to management of thrombosis in patients.
Downloads
Download data is not yet available.
Citations
1. Tawil N, Adnani L, Rak J. Coagulome and tumor microenvironment: impact of oncogenes, cellular heterogeneity and extracellular vesicles. Bleeding Thromb Vasc Biol 2024;3:109. DOI: https://doi.org/10.4081/btvb.2024.109
2. Gezelius E, Flou Kristensen A, Bendahl PO, et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. PLoS One 2018;13:e0207387. DOI: https://doi.org/10.1371/journal.pone.0207387
3. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007;106:32-37. DOI: https://doi.org/10.1159/000101798
4. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8:11. DOI: https://doi.org/10.1038/s41572-022-00336-y
5. Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol 2021;192:803-18. DOI: https://doi.org/10.1111/bjh.17172
6. Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience 2016;10:649. DOI: https://doi.org/10.3332/ecancer.2016.649
7. Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 2016;132:917-30. DOI: https://doi.org/10.1007/s00401-016-1620-7
8. Magnus N, Gerges N, Jabado N, Rak J. Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype. J Thromb Haemost 2013;11:1197-200. DOI: https://doi.org/10.1111/jth.12242
9. Galmiche A, Rak J, Roumenina LT, Saidak Z. Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer 2022;8:369-83. DOI: https://doi.org/10.1016/j.trecan.2021.12.008
10. Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res 2016;140:S12-7. DOI: https://doi.org/10.1016/S0049-3848(16)30092-5
11. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009;22:9-23. DOI: https://doi.org/10.1016/j.beha.2008.12.001
12. Mahé I, Benarroch S, Djennaoui S, et al. Cancer-associated thrombosis: what is new? Curr Opin Oncol 2025;37:150-7. DOI: https://doi.org/10.1097/CCO.0000000000001125
13. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb. Haemost 2007;5:632-4. DOI: https://doi.org/10.1111/j.1538-7836.2007.02374.x
14. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23:e334-7.
15. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712-23. DOI: https://doi.org/10.1182/blood-2013-04-460121
16. Tawil N, Bassawon R, Meehan B, et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv 2021;5:1682-94. DOI: https://doi.org/10.1182/bloodadvances.2020002998
17. Pelegrín-Mateo FJ, Zambrano CB, Vázquez EB, et al. Cancer genetic profile and risk of thrombosis. Eur J Intern Med 2025;136:19-26. DOI: https://doi.org/10.1016/j.ejim.2025.04.004
18. Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost 2023;21:1397-408. DOI: https://doi.org/10.1016/j.jtha.2023.02.029
19. Lanting V, Oskam M, Wilmink H, et al. The role of germline and somatic mutations in predicting cancer-associated thrombosis: a narrative review. Curr Opin Hematol 20255;32:138-45. DOI: https://doi.org/10.1097/MOH.0000000000000861
20. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017;130:1499-506. DOI: https://doi.org/10.1182/blood-2017-03-743211
21. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus J Thromb Haemost 2011;9:2313-21. DOI: https://doi.org/10.1111/j.1538-7836.2011.04465.x
22. Kakkar AK, Lemoine NR, Scully MF, et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995;82:1101-4. DOI: https://doi.org/10.1002/bjs.1800820831
23. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer 1996;32A:2438-50. DOI: https://doi.org/10.1016/S0959-8049(96)00396-6
24. Lecumberri R, Marcos-Jubilar M, Hermida J, Ruiz-Artacho P. Differences in the Outcome of cancer-associated thrombosis depending on cancer type. Thromb Haemost 2025;125:1053-9. DOI: https://doi.org/10.1055/a-2535-7400
25. Rak J. Ras oncogenes and tumour vascular interface. In: A. Thomas-Tikhonenko (ed.), Cancer genome and tumor microenvironment. New York, Springer; 2009. pp. 133-65. DOI: https://doi.org/10.1007/978-1-4419-0711-0_7
26. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. DOI: https://doi.org/10.1038/nm1087
27. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
28. Spinelli C, Adnani L, Meehan B, et al. Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying EGFR. Nat Commun 2024;15:2865. DOI: https://doi.org/10.1038/s41467-024-46597-x
29. Bauer AT, Gorzelanny C, Gebhardt C, et al. Schneider, Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treat Rev 2022;102:102322. DOI: https://doi.org/10.1016/j.ctrv.2021.102322
30. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85-8. DOI: https://doi.org/10.1126/science.8465203
31. Rak J, Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev 2000;19:93-6. DOI: https://doi.org/10.1023/A:1026516920119
32. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-41. DOI: https://doi.org/10.1182/blood-2004-05-2042
33. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-13. DOI: https://doi.org/10.1158/0008-5472.CAN-04-3376
34. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400. DOI: https://doi.org/10.1038/nature03357
35. Milsom CC, Yu JL, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008;68:10068-76. DOI: https://doi.org/10.1158/0008-5472.CAN-08-2067
36. Dunbar A, Bolton KL, Devlin SM, et al. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors Blood 2021;137:2103-13. DOI: https://doi.org/10.1182/blood.2020007488
37. Ades S, Kumar S, Alam M, et al. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. J Thromb Haemost 2015;13:998-1003. DOI: https://doi.org/10.1111/jth.12910
38. Verso M, Moik F, Graziani M, Cohen AT. Targeted anti-cancer agents and risk of venous thromboembolism. Haematologica 2024;109:3868-78. DOI: https://doi.org/10.3324/haematol.2023.284778
39. Mukasa A, Wykosky J, Ligon KL, et al. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci USA 2010;107:2616-21. DOI: https://doi.org/10.1073/pnas.0914356107
40. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-26. DOI: https://doi.org/10.1038/nrc3599
41. Jo J, Diaz M, Horbinski C, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro Oncol 2023;25:1381-94. DOI: https://doi.org/10.1093/neuonc/noad059
42. Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023;141:1322-36. DOI: https://doi.org/10.1182/blood.2022017858
43. Alshehri FS, Alloghbi A, Alshalani A, et al. Cancer-associated thrombosis (CAT); mechanisms and treatment options. Thromb J 2025;23:116. DOI: https://doi.org/10.1186/s12959-025-00795-9
44. D'Asti E, Rak J. Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy. Thromb Res 2016;140:S37-43. DOI: https://doi.org/10.1016/S0049-3848(16)30096-2
45. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012;19:5543-52. DOI: https://doi.org/10.1182/blood-2012-01-402156
46. Riedl J, Preusser M, Nazari PM, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017;129:1831-9. DOI: https://doi.org/10.1182/blood-2016-06-720714
47. Furuta T, Negoto T, Miyoshi H, et al. Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas. J Neurooncol 2023;164:633-41. DOI: https://doi.org/10.1007/s11060-023-04447-8
48. Le Chapelain O, Ho-Tin-Noé B. Intratumoral Platelets: harmful or incidental bystanders of the tumor microenvironment? Cancers (Basel) 2022;14:2192. DOI: https://doi.org/10.3390/cancers14092192
49. Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res 2009;148:31-41. DOI: https://doi.org/10.1007/978-0-387-79962-9_3
50. Morimoto-Kamata R, Ohkura N. Paclitaxel and vinblastine increase plasminogen activator inhibitor-1 production in human breast cancer MCF-7 cells but not MDA-MB-231 cells. Biol Pharm Bull 2024;47:1494-503. DOI: https://doi.org/10.1248/bpb.b24-00291
51. Koizume S, Yokota N, Miyagi E, et al. Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Mol Cancer Res 2009;7:1928-36. DOI: https://doi.org/10.1158/1541-7786.MCR-09-0372
52. Krafft C, Wilhelm K, Eremin A, et al. A specific spectral signature of serum and plasma-derived extracellular vesicles for cancer screening. Nanomedicine 2017;13:835-41. DOI: https://doi.org/10.1016/j.nano.2016.11.016
53. Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep 2013;33:e00064. DOI: https://doi.org/10.1042/BSR20130057
54. Tinholt M, Tekpli X, Torland LA, et al. The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy. J Thromb Haemost 2024;22:1319-35. DOI: https://doi.org/10.1016/j.jtha.2024.01.003
55. Wahab R, Hasan MM, Azam Z, et al. The role of coagulome in the tumor immune microenvironment. Adv Drug Deliv Rev 2023;200:115027. DOI: https://doi.org/10.1016/j.addr.2023.115027
56. Quintanilla M, Montero-Montero L, Renart J, Martín-Villar E. Podoplanin in inflammation and cancer. Int J Mol Sci 2019;20:707. DOI: https://doi.org/10.3390/ijms20030707
57. Ma L, Francia G, Viloria-Peti A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-73. DOI: https://doi.org/10.1158/0008-5472.CAN-04-3156
58. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-42. DOI: https://doi.org/10.1182/blood.V89.7.2429
59. Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013;131:162-5. DOI: https://doi.org/10.1016/j.thromres.2012.09.020
60. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558-67. DOI: https://doi.org/10.1021/bi00341a041
61. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36:888-906. DOI: https://doi.org/10.1055/s-0030-1267043
62. Dvorak HF, Quay SC, Orenstein NS, et al. Tumor shedding and coagulation. Science 1981;212:923-4. DOI: https://doi.org/10.1126/science.7195067
63. Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem 2012;287:43565-72. DOI: https://doi.org/10.1074/jbc.M112.401760
64. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013;122:1873-80. DOI: https://doi.org/10.1182/blood-2013-04-460139
65. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106:1604-11. DOI: https://doi.org/10.1182/blood-2004-03-1095
66. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-5. DOI: https://doi.org/10.1073/pnas.96.5.2311
67. Nieuwland R. Cellular origin of microparticles exposing tissue factor in cancer: a mixed double? J Thromb Haemost 2008;6:1514-6. DOI: https://doi.org/10.1111/j.1538-7836.2008.03069.x
68. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-7. DOI: https://doi.org/10.1111/j.1538-7836.2004.00972.x
69. Coumans FAW, Brisson AR, Buzas EI, et al. Methodological guidelines to study extracellular vesicles. Circ Res 2017;120:1632-48. DOI: https://doi.org/10.1161/CIRCRESAHA.117.309417
70. Hendrix AL, Pinheiro L, Thery C, et al. Extracellular vesicle analysis. Nat Rev Methods Primers 2023;3:57. DOI: https://doi.org/10.1038/s43586-023-00240-z
71. Bonifay A, Cointe S, Plantureux L, et al. Update on tissue factor detection in blood in 2024: a narrative review. Hamostaseologie 2024;44:368-76. DOI: https://doi.org/10.1055/a-2381-6854
72. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles 2024;3:e12404.
73. Lucotti S, Ogitani Y, Kenific CM, et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell 2025;20:1642-61. DOI: https://doi.org/10.1016/j.cell.2025.01.025
74. Gil-Bernabe AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012;119:3164-75. DOI: https://doi.org/10.1182/blood-2011-08-376426
75. Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res 2007;120:S22-8. DOI: https://doi.org/10.1016/S0049-3848(07)70127-5
76. Buijs JT, Versteeg HH. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb Res 2020;191:S43-9. DOI: https://doi.org/10.1016/S0049-3848(20)30396-0
77. Turizo MJF, Patell R, Zwicker JI. Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis. Bleeding Thromb Vasc Biol 2024;3:120. DOI: https://doi.org/10.4081/btvb.2024.120
78. Xing CY, Tarumi T, Liu J, et al. Distribution of cardiac output to the brain across the adult lifespan. J Cereb Blood Flow Metab 2017;37:2848-56. DOI: https://doi.org/10.1177/0271678X16676826
79. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32:11-23. DOI: https://doi.org/10.1055/s-2006-933336
80. Tehrani M, Friedman TM, Olson JJ, Brat DJ. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 2008;18:164-71. DOI: https://doi.org/10.1111/j.1750-3639.2007.00108.x
81. Diaz M, Jo J, Smolkin M, et al. Risk of venous thromboembolism in grade II-IV Gliomas as a function of molecular subtype. Neurology 2021;96:e1063-9. DOI: https://doi.org/10.1212/WNL.0000000000011414
82. Riedl J, Ay C. Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost 2019;45:334-41. DOI: https://doi.org/10.1055/s-0039-1688493
83. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost 2014;40:325-31. DOI: https://doi.org/10.1055/s-0034-1370791
84. Kapteijn MY, Bakker N, Koekkoek JAF, et al. Venous thromboembolism in patients with glioblastoma: molecular mechanisms and clinical implications. Thromb Haemost 2025;125:421-34. DOI: https://doi.org/10.1055/s-0044-1789592
85. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640-6. DOI: https://doi.org/10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E
86. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 2015;124:87-94. DOI: https://doi.org/10.1007/s11060-015-1805-2
87. Ornstein DL, Meehan KR, Zacharski LR. The coagulation system as a target for the treatment of human gliomas. Semin Thromb Hemost 2002;28:19-28. DOI: https://doi.org/10.1055/s-2002-20561
88. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397-405. DOI: https://doi.org/10.1038/labinvest.3700070
89. Ruf W, Disse J, Carneiro- TC, et al. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011;9:s306-15. DOI: https://doi.org/10.1111/j.1538-7836.2011.04318.x
90. Gessler F, Voss V, Dützmann S, et al. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 2010;165:1312-22. DOI: https://doi.org/10.1016/j.neuroscience.2009.11.049
91. Jeon HM, Kim JY, Cho HJ, et al. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer Cell 2023;41:1480-97. DOI: https://doi.org/10.1016/j.ccell.2023.06.007
92. Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations, Proc Natl Acad Sci USA 2014;111:3544-9. DOI: https://doi.org/10.1073/pnas.1314118111
93. Chittiboina P, Connor Jr DE, Caldito G, et al. Occult tumors presenting with negative imaging: analysis of the literature J Neurosurg 2012;116:1195-203. DOI: https://doi.org/10.3171/2012.3.JNS112098
94. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073-113. DOI: https://doi.org/10.1093/neuonc/noaa106
95. Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet 2016;48:768-76. DOI: https://doi.org/10.1038/ng.3590
96. Maletzki C, Freitag T, Hempelmann A, et al. Tumor treating fields alter local coagulation dynamics in glioblastoma patients. Neurotherapeutics 2025;22:e00715. DOI: https://doi.org/10.1016/j.neurot.2025.e00715
97. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol 2017;14:7) 434-52. DOI: https://doi.org/10.1038/nrclinonc.2016.204
98. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-401. DOI: https://doi.org/10.1126/science.1254257
99. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. DOI: https://doi.org/10.1016/j.ccr.2006.02.019
100. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110. DOI: https://doi.org/10.1016/j.ccr.2009.12.020
101. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482:226-31. DOI: https://doi.org/10.1038/nature10833
102. Andrade AF, Chen CCL, Jabado N. Oncohistones in brain tumors: the soil and seed. Trends Cancer 2023;9:444-55. DOI: https://doi.org/10.1016/j.trecan.2023.02.003
103. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469-74. DOI: https://doi.org/10.1038/nature26000
104. Chen Y, Fei W, Shi Y, et al. Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study. Front Pediatr 2025;13:1595223. DOI: https://doi.org/10.3389/fped.2025.1595223
105. Wei X, Meel MH, Breur M, et al. Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas. Acta Neuropathol Commun 2021;9:142. DOI: https://doi.org/10.1186/s40478-021-01243-1
106. Jahouri SM, Tawil L, Jalali N, et al. Elucidating the extracellular vesicle signature of K27M oncohistone-driven pediatric high-grade gliomas. Proc. CanSEV2025 Annual Meet. Canadian Society for Extracellular Vesicles, Montrea; 2025.
107. Kaye B, Ali A, Correa Bastianon Santiago RA, et al. The role of EGFR Amplification in deep venous thrombosis occurrence in IDH wild-type glioblastoma, Curr Oncol 2023;30:4946-56. DOI: https://doi.org/10.3390/curroncol30050373
108. Chahal M, Abdulkarim B, Xu Y, et al. O6-methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme. Mol Cancer Ther 2012;11:2440-50. DOI: https://doi.org/10.1158/1535-7163.MCT-11-0977
109. Garnier D, Meehan B, Kislinger T, et al. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol 2018;20:236-48. DOI: https://doi.org/10.1093/neuonc/nox142
110. Meehan B, Adnani L, Zhu X, et al. Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells. Acta Neuropathol Commun 2025;13:64. DOI: https://doi.org/10.1186/s40478-025-01984-3
111. Hazan RB, Kang L, Whooley BP, Borgen PI. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 1997;4:399-411. DOI: https://doi.org/10.3109/15419069709004457
112. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017;31:326-41. DOI: https://doi.org/10.1016/j.ccell.2017.02.009
113. Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 2017;32:42-56. DOI: https://doi.org/10.1016/j.ccell.2017.06.003
114. Adnani L, Meehan B, Kim M, et al. Immune cell infiltration into brain tumor microenvironment is mediated by Rab27-regulated vascular wall integrity. Sci Adv 2025;11:eadr6940. DOI: https://doi.org/10.1126/sciadv.adr6940
115. Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 2019;178:835-49. DOI: https://doi.org/10.1016/j.cell.2019.06.024
116. Garofano L, Migliozzi S, Oh YT, et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer 2021;2:141-56. DOI: https://doi.org/10.1038/s43018-020-00159-4
117. Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013;110:8644-9. DOI: https://doi.org/10.1073/pnas.1221478110
118. Bastola S, Pavlyukov MS, Yamashita D, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nat Commun 2020;11:4660. DOI: https://doi.org/10.1038/s41467-020-18189-y
119. Adnani L, Kassouf J, Meehan B, et al. Angiocrine extracellular vesicles impose mesenchymal reprogramming upon proneural glioma stem cells. Nat Commun 2022;13:5494. DOI: https://doi.org/10.1038/s41467-022-33235-7
120. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 2012;14:iv73-iv80. DOI: https://doi.org/10.1093/neuonc/nos197
121. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010;116:815-8. DOI: https://doi.org/10.1182/blood-2009-10-250639
122. de Bono JS, Harris JR, Burm SM, et al. Systematic study of tissue factor expression in solid tumors. Cancer Rep (Hoboken) 2023;6:e1699. DOI: https://doi.org/10.1002/cnr2.1699
123. Bastida E, Ordinas A, Escolar G, Jamieson GA. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 1984;64:177-84. DOI: https://doi.org/10.1182/blood.V64.1.177.bloodjournal641177
124. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012;10:1363-70. DOI: https://doi.org/10.1111/j.1538-7836.2012.04754.x
125. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 2018;19:213-28. DOI: https://doi.org/10.1038/nrm.2017.125
126. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30. DOI: https://doi.org/10.1016/j.ccr.2010.12.014
127. Unruh D, Mirkov S, Wray B, et al. Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1-mutant gliomas. Clin Cancer Res 2019;25:747-59. DOI: https://doi.org/10.1158/1078-0432.CCR-18-1222
128. Sun C, Xiao L, Zhao Y, et al. Wild-type IDH1 and mutant IDH1 opposingly regulate podoplanin expression in glioma. Transl Oncol 2020;13:100758. DOI: https://doi.org/10.1016/j.tranon.2020.100758
129. Costa B, Eisemann T, Strelau J, et al. Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells. Blood Adv 2019;3:1092-102. DOI: https://doi.org/10.1182/bloodadvances.2018015966
130. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-24. DOI: https://doi.org/10.1038/ncb1725
131. Kilinc S, Paisner R, Camarda R, et al. Oncogene-regulated release of extracellular vesicles. Dev Cell 2021;56:1989-2006. DOI: https://doi.org/10.1016/j.devcel.2021.05.014
132. Choi D, Lee TH, Spinelli C, et al. Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation. Semin Cell Dev Biol 2017;67:11-22. DOI: https://doi.org/10.1016/j.semcdb.2017.01.003
133. Tawil N, Chennakrishnaiah S, Bassawon R, et al. Single cell coagulomes as constituents of the oncogene-driven coagulant phenotype in brain tumours. Thromb Res 2018;164:S136-42. DOI: https://doi.org/10.1016/j.thromres.2018.01.021
134. Tawil N, Bassawon R, Rak J. Oncogenes and Clotting factors: the emerging role of tumor cell genome and epigenome in cancer-associated thrombosis. Semin Thromb Hemost 2019;45:373-84. DOI: https://doi.org/10.1055/s-0039-1687891
135. Couturier CP, Ayyadhury S, Le PU, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun 2020;11:3406. DOI: https://doi.org/10.1038/s41467-020-17186-5
136. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost 2007;5:2550-2. DOI: https://doi.org/10.1111/j.1538-7836.2007.02766.x
137. Shaker H, Harrison H, Clarke R, et al. Tissue factor promotes breast cancer stem cell activity in vitro. Oncotarget 2017;8:25915-27. DOI: https://doi.org/10.18632/oncotarget.13928
138. Schaffner F, Yokota N, Carneiro-Lobo T, et al. Endothelial protein C receptor function in murine and human breast cancer development, PLoS One 2013;8:e61071. DOI: https://doi.org/10.1371/journal.pone.0061071
139. Dützmann S, Gessler F, Harter PN, et al. The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas. Cell Adh Migr 2010;4:515-22. DOI: https://doi.org/10.4161/cam.4.4.12660
140. Greenwald AC, Darnell NG, Hoefflin R, et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell 2024;187:2485-501. DOI: https://doi.org/10.1016/j.cell.2024.03.029
141. Kapteijn MY, Zwaan S, Ter Linden E, et al. Temozolomide and lomustine induce tissue factor expression and procoagulant activity in glioblastoma cells in vitro. Cancers (Basel) 2023;15:2347. DOI: https://doi.org/10.3390/cancers15082347
142. Mackman N, Tawil N, Rak J. Tissue factor at the crossroads of coagulation and radiation response in glioblastoma. J Thromb Haemost 2024;22:3-6. DOI: https://doi.org/10.1016/j.jtha.2023.10.018
143. Alalami H, Hu J, Rudnick J, et al. INNV-16. Off-label use of vorasidenib in IDH-mutant grade 3 and 4 gliomas: a single-institution experience Neuro Oncol 2025;27:v228. DOI: https://doi.org/10.1093/neuonc/noaf201.0905
144. Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. Nature 2015;528:93-8. DOI: https://doi.org/10.1038/nature16071
145. Hausmann D, Hoffmann DC, Venkataramani V, et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature 2023;613:179-86. DOI: https://doi.org/10.1038/s41586-022-05520-4
146. Mangena V, Chanoch-Myers R, Sartore R, et al. Glioblastoma cortical organoids recapitulate cell-state heterogeneity and intercellular transfer. Cancer Discov 2025;15:299-315. DOI: https://doi.org/10.1158/2159-8290.CD-23-1336
147. Das K, Keshava S, Ansari SA, et al. Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effec., Blood 2021;137:3428-42. DOI: https://doi.org/10.1182/blood.2020008417
148. Sartori MT, Della PA, Ballin A, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost 2013;110:378-85. DOI: https://doi.org/10.1160/TH12-12-0957
149. Sartori MT, Della PA, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011;104:225-31. DOI: https://doi.org/10.1007/s11060-010-0462-8
150. Melnichnikova O, Zhilenkova Y, Sirotkina O, et al. Circulating Small extracellular vesicles profiling and thrombin generation as potential markers of thrombotic risk in glioma patient. Front Cardiovasc Med 2022;9:789937. DOI: https://doi.org/10.3389/fcvm.2022.789937
151. Gonzalez-Delgado R, Muñoz NM, Carlos-Alcalde W, et al. Role of circulating mitochondria in venous thrombosis in glioblastoma. J Thromb Haemost 2023;21:2202-12. DOI: https://doi.org/10.1016/j.jtha.2023.04.036
Supporting Agencies
Canadian Institutes of Health Research, Cancer Research Society, Fondation Charles Bruneau, Fondation CIBC, Cole Foundation, Canada Foundation for Innovation, NFRF-ExplorationHow to Cite
1.
Rak J. Mechanistic insights into cancer-associated thrombosis in brain cancer. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/430
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Nadim Tawil, Lata Adnani, Janusz Rak, Coagulome and tumor microenvironment: impact of oncogenes, cellular heterogeneity and extracellular vesicles , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
